Chemoprevention of Oral Premalignant Lesions | NCT00036283 | Trialant

Chemoprevention of Oral Premalignant Lesions | NCT00036283 | Trialant

Outcomes Module

Primary Outcomes

Measure	Description	Time Frame
To evaluate the efficacy of celecoxib in subjects with Early or Advanced oral premalignant lesion (OPL)
by both clinical response (reduction in size of all lesions,
prevention of growth in the index lesion and of any new lesions)
and histological response (change in histological grade).
To evaluate the safety of chronic multiple dosing of celecoxib in this patient population.

Secondary Outcomes

Measure	Description	Time Frame
To evaluate the treatment effects in modulating the expression of genomic and proliferative markers after 12 weeks of treatment with study drug, followed by 12 weeks off study drug.

Contacts/Locations Module

Intervention Browse Module